ScanSource Is Worth Keeping An Eye On
ScanSource (SCSC) delivered a blowout Q4, beating consensus with 17% revenue growth and strong FY27 guidance, yet shares saw only a muted reaction. SCSC trades at 7.2x EV/EBITDA and ≤13x P/FCF on FY27 guidance, a notable discount to peers, with potential upside if growth sustains and multiples re-rate. The MicroAge acquisition could expand addressable markets, add services, and enhance exposure to cloud and AI, but integration and execution risks remain.